Related by context. All words. (Click for frequent words.) 73 ZFP Therapeutic TM 69 Factor VIIa 68 Prodarsan R 67 ZFP Therapeutics 67 INS# [001] 66 oral prodrug 66 torezolid phosphate 66 pharmacological chaperone 66 isoform selective 66 HDL Selective Delipidation 66 ALN TTR 65 ONCONASE R 65 preclinical 65 HDL Mimetic Peptide 65 nucleotide analog 65 antibody MAb 65 INCB# [001] 65 OncoVex 65 Phase 2b Clinical Trial 65 Hepatitis C Virus HCV 65 diabetic neuropathy 65 EVIZON TM 65 Archexin 65 CYT# potent vascular disrupting 65 Squalamine 64 mGluR2 NAM 64 inhibit metastasis 64 FOLOTYN ® 64 Entry Inhibitor 64 preclinical efficacy 64 ALN TTR# 64 Phase 2a clinical trials 64 investigational humanized monoclonal antibody 64 Tesetaxel 64 Prodarsan ® 64 CD# CEA 64 telomerase therapeutic 64 Curaxin CBLC# 64 NTDDS 64 selective androgen receptor modulator 64 immunotherapeutic vaccine 64 trastuzumab DM1 T DM1 64 Cetrorelix 64 orally inhaled migraine 64 HTS assay 64 targeted radiotherapeutic 64 forodesine 64 therapeutic monoclonal antibody 64 IRX 2 63 kidney urologic 63 Personalized Immunotherapy 63 ALN PCS 63 NovaBay Aganocide compounds 63 Exherin TM 63 targeting CD# 63 CCR9 antagonist 63 Janus kinase 63 Phase IIb clinical trials 63 mda 7 63 Panzem 63 gastro intestinal inflammation 63 TKM ApoB 63 Achieves Primary Endpoint 63 histone deacetylase HDAC inhibitor 63 NPC 1C 63 Tarvacin TM 63 LBH# 63 HQK 63 Neo Kidney Augment 63 DPX Survivac 63 cannabinor 63 CCR5 mAb 63 GVAX ® 63 synthetic retinoid 63 LEAPS TM 63 Immunotherapeutic 63 EGS# 63 Therapeutic Vaccine 63 SCIB1 63 vascular disrupting agent 63 Unit Dose Budesonide 63 Sphingomab TM 63 Hedgehog antagonist 62 Fx #A 62 ZFP TF 62 nicotinic alpha 7 62 vidofludimus 62 Fabry Disease 62 MVA BN R 62 Successfully Completes Phase 62 including eniluracil ADH 62 Anavex #-# 62 Clinical Trial Results 62 NEUGENE R 62 JAK2 inhibitor 62 Safinamide 62 BiTE R 62 Phase 2b Trial 62 immunotherapeutics 62 R#/MEM # 62 mertansine 62 GALNS 62 CMV vaccine 62 otelixizumab 62 GLP toxicology studies 62 novel therapeutic antibodies 62 prophylactic vaccine 62 next generation URAT1 62 systemic RNAi therapeutic 62 CTAP# Capsules 62 Xyfid TM 62 Presents Preclinical Data 62 PRTX 62 Preclinical Study 62 novel VDA molecule 62 Drug Candidate 62 Guanilib 62 Solazed TM 62 lucinactant 62 HuMax EGFr 62 non nucleoside HCV 62 Hepatitis C HCV 62 immunoregulation 62 Protexia R 62 R#/MEM 62 Campath alemtuzumab 62 Presents Preclinical 62 cMET 62 AAG geldanamycin analog 62 transthyretin TTR mediated amyloidosis 62 Xcytrin R 62 Ocrelizumab 62 investigational monoclonal antibody 62 molecular imaging radiopharmaceutical 62 KRN# 62 JAK2 Inhibitor 62 compound AEZS 62 immune modulator 62 CCX# 62 Cethromycin 62 NV1FGF 62 PI3K/mTOR 62 sodium thiosulfate STS 62 TransVax 62 Chimigen TM 62 JAK inhibitor 62 antiviral therapeutics 62 DermaVir Patch 62 RNAi therapeutic targeting 62 Panzem R 62 Altastaph 62 candidate CRLX# 62 rxRNA 62 Vitaxin 62 siRNA therapeutics 62 Spiegelmer ® 62 Metastatic Melanoma 62 Azixa 62 CRLX# 62 tezampanel NGX# 62 TTR amyloidosis 61 Elagolix 61 oral nucleoside analogue 61 Surfaxin LS 61 Thiovir 61 HIV integrase inhibitors 61 MyVax R 61 OncoVEX GM CSF 61 Completes Patient Enrollment 61 TLR antagonists 61 ATL# [001] 61 Inhalation Solution 61 talactoferrin 61 torezolid 61 Tyrosine Kinase Inhibitor 61 tanespimycin 61 Preclinical studies suggest 61 KSP inhibitor 61 PANVAC VF 61 RGB # 61 alagebrium 61 siRNA therapeutic 61 MEK inhibitor 61 TRO# 61 Ecallantide 61 RNAi Therapeutic 61 Viprovex TM 61 Phase 2a clinical 61 MCSP respectively 61 DCVax 61 Cx# [002] 61 Tovaxin ® 61 Universal Flu Vaccine 61 BRIM2 61 novel peptide 61 apricitabine ATC 61 Respiratory Syncytial Virus RSV 61 Homspera TM 61 Allovectin 7 61 HspE7 61 EP #R 61 pertuzumab 61 Systemic Delivery 61 Symadex 61 Aganocide ® 61 #th Annual Interscience 61 exon skipping 61 CRMD# 61 Hedgehog pathway inhibitor 61 Initiates Phase II 61 Rhucin ® recombinant 61 recurrent glioblastoma multiforme 61 delipidation 61 multi kinase inhibitor 61 Ceflatonin 61 alvespimycin 61 Vicriviroc 61 HDL Therapy 61 tiapamil 61 Multimeric 61 oncolytic virus therapies 61 Phase IIb Trial 61 Phase III Pivotal 61 EVIZON TM squalamine lactate 61 Vaxfectin ® 61 Sangamo BioSciences Announces 61 immunotherapeutic approaches 61 LymphoStat B belimumab 61 human IgG1 monoclonal 61 P#X# 61 PROSTVAC TM 61 NicVAX TM 61 Azedra 61 acetonide FA 61 OvaRex R 61 phase IIb clinical 61 BiovaxID TM 61 personalized immunotherapy 61 refractory gout 61 MKC# MKC# PP 61 Reports Preclinical Data 61 Meets Primary Endpoint 61 XmAb ® 61 liposomal formulation 61 HCV polymerase 61 LEVADEX TM 61 Behcet uveitis 61 DCVax R 61 IND submission 61 Curaxin 61 epigenetic therapies 61 volociximab 61 immune modulation 61 XmAb 61 Capesaris 61 Zemiva TM 61 BRAF inhibitor 61 LymphoStat B TM 61 Romidepsin 61 sd rxRNA compounds 61 Aflibercept 61 humanized monoclonal 61 Atiprimod 61 Bicifadine 61 compound perifosine 61 trial evaluating PRX# 61 Trofex 61 NP2 Enkephalin 61 ospemifene 61 PNP inhibitor 61 NeuroVax TM 61 Laquinimod 61 POSIDUR TM ELADUR TM 61 phase 2a 60 HCV protease inhibitors 60 soluble tumor necrosis 60 small molecule activators 60 Kinase Inhibitor 60 nanoviricides 60 CEQ# 60 non nucleoside 60 non nucleoside inhibitor 60 NYSE Amex PBTH 60 Phase 1b 60 CINTREDEKIN BESUDOTOX 60 candidate deforolimus 60 anti CD3 monoclonal 60 delafloxacin 60 Lixivaptan 60 Talabostat 60 Vaxfectin R formulated 60 CB2 selective receptor agonist 60 MyVax ® 60 Phase Ib study 60 OHR/AVR# 60 LibiGel ® 60 Tasimelteon 60 NEUMUNE 60 ELACYT 60 Aerosurf 60 hepatitis C HCV 60 CR# vcMMAE 60 autologous cellular immunotherapy 60 Allovectin 7 R 60 JAK inhibitors 60 TKB# 60 Aurora Kinase 60 novel ZFP TFs 60 Phase Ib clinical 60 Aganocide 60 lintuzumab 60 Phase 2a Clinical Trial 60 Phenoptin 60 Alequel 60 integrase inhibitor 60 receptor tyrosine kinase inhibitor 60 entinostat 60 GRNCM1 60 Aliskiren 60 Dalbavancin 60 cytomegalovirus CMV 60 neuroregenerative 60 Vilazodone 60 NU# direct 60 viral kinetics 60 aerosolized KL4 surfactant 60 fosbretabulin 60 PSN# [002] 60 Tarvacin Anti Viral 60 ostarine 60 Pyridorin 60 novel immunotherapeutic 60 VitiGam 60 ThGRF 60 sorafenib tablets 60 polymerase inhibitor 60 Denufosol 60 telomerase inhibitor drug 60 visilizumab 60 Phase IIb Clinical Trial 60 ImmunoVEX HSV2 60 Microplasmin 60 MKC# MT 60 Preclinical Efficacy 60 predictive toxicology 60 AEG# 60 Blinatumomab 60 immunomodulatory 60 SYN# 60 Phase 2a trial 60 TRIOLEX 60 TMC# [002] 60 HuLuc# 60 KL4 surfactant 60 HDAC Inhibitor 60 ZFN TM 60 Pemphigus Vulgaris 60 IAP inhibitors 60 eTag assays 60 small molecule thrombopoietin 60 QLT# 60 Beta catenin pathway 60 Sphingomab 60 Cintredekin Besudotox 60 IL# PE#QQR 60 PLK1 SNALP 60 Phase III Clinical Trial 60 reslizumab 60 Tß4 60 Bendavia 60 dasatinib Sprycel 60 Granulocyte Colony Stimulating Factor 60 immuno therapeutic 60 Prodarsan 60 multicenter Phase II 60 Virulizin ® 60 OXi# 60 oral ghrelin agonist 60 Cardiotoxicity 60 Lpathomab 60 Pivotal Phase III 60 agonistic human 60 Factor Receptor 60 MEK Inhibitor 60 purinergic receptors P#X# 60 alemtuzumab Campath 60 Memryte 60 phase IIa clinical 60 RhuDex 60 NS#/#A protease 60 JAK1 60 HCD# [002] 60 midstage trials 60 Pharmacokinetics PK 60 Initiates Clinical 60 ACTEMRA TM 60 MEK inhibitor RDEA# 60 Pre Exposure Prophylaxis 60 Dendritic Cells 60 Initiates Phase 60 Fc fusion protein 60 LEVADEX ™ 60 RAV# 60 SMT C# 60 IMA# 60 Hsp# Inhibitor 60 Pivotal Phase 60 PHX# 60 Begins Dosing 60 anti CD3 antibody 60 MPS IVA 60 PDE4 inhibitor 60 humanised monoclonal antibody 60 P#X# antagonist 60 velafermin 60 protein tyrosine phosphatase 1B 60 RECOTHROM ® 60 romazarit 60 RhuDex ® 60 Edward Lanphier Sangamo 60 CINQUIL 60 preclinically 60 Monoclonal Antibody 60 vivo validation 60 Alzhemed TM 60 MAGE A3 ASCI 60 huC# DM4 60 Hedgehog Pathway Inhibitor 60 ZFP TFs 60 small molecule tyrosine 60 recombinant biopharmaceutical 60 predictive biomarkers 60 targeted antifolate 60 Leber Hereditary Optic Neuropathy 60 MDRNA proprietary 60 Phase Ib clinical trials 60 radezolid 60 Phase 2b clinical 60 Initiate Phase 60 BrachySil TM 60 RNAi Therapeutics 59 URG# 59 Phase 2a 59 orally administered inhibitor 59 phase IIb study 59 atacicept 59 Civacir 59 investigational antibiotic 59 Pagoclone 59 LEP ETU 59 II Clinical Trial 59 Angiocept 59 phase IIa 59 Inhaled nitric oxide 59 proteasome inhibitor 59 CB2 receptor selective 59 Bioral Amphotericin B 59 Pafuramidine 59 DermaVir 59 MAXY G# 59 ganaxolone 59 Elvitegravir 59 PhG alpha 1 59 Amigal 59 trastuzumab DM1 59 Ketotransdel 59 ZFN modified 59 ARRY # 59 Dapagliflozin 59 glucokinase activator 59 Onconase 59 PEGylated interferon beta 1a 59 SNT-MC#/idebenone 59 receptor inhibitor 59 Diamyd ® 59 cartilage regeneration 59 KL4 Surfactant 59 squalamine 59 Ozarelix 59 small molecule defensin 59 diarrhea predominant irritable 59 antisense drug 59 hypereosinophilic syndrome 59 Polymerase Inhibitor 59 cancer immunotherapies 59 Randomized Phase 59 Traficet EN 59 Prostate AdenoCarcinoma Treatment 59 Enkephalin 59 castrate resistant prostate cancer 59 RNAi therapeutic targeting PCSK9 59 Initiate Clinical Trial 59 Phase 1a clinical 59 Thiarabine 59 Phase 2a Trial 59 preclinical studies 59 darapladib 59 Alvine Pharmaceuticals 59 monoclonal antibody therapeutics 59 Catena ® 59 HPV cervical cancer 59 Bezielle 59 Exelixis compounds 59 Oral NKTR 59 Sangamo ZFP TF 59 Oxytrex TM 59 inflammatory demyelinating 59 PrevOnco 59 Vaxfectin R adjuvant 59 ThermoDox R 59 Brussels THR 59 Vaccine Adjuvant 59 Aurora kinase inhibitors 59 mitogen activated ERK kinase 59 oral FTY# 59 MOR# 59 Initiated Phase 59 systemic fungal infections 59 IAP inhibitor 59 PEG PAL 59 somatostatin analogue 59 aldehyde dehydrogenase ALDH2 deficiency 59 bardoxolone 59 humanized monoclonal antibody 59 Xanafide 59 Panzem ® 59 Trodusquemine MSI 59 M# rationally 59 novel immunotherapies 59 HuMax TAC 59 oncolytic viruses 59 CIPN 59 Rigel R# 59 fibrotic diseases 59 OncoVEX 59 Factor IX 59 acadesine 59 molecular biomarkers 59 Phase IIb trials 59 Cancer Vaccines 59 acyclovir Lauriad R 59 Pimavanserin 59 Cethrin R 59 ELADUR ™ 59 TACI Ig 59 Sangamo BioSciences 59 Protexia ® 59 PI3 kinase inhibitors 59 PD LID 59 ATL/TV# 59 A3 adenosine receptor 59 GSK# [002] 59 anti CD3 59 virus HCV protease inhibitor 59 DXL# 59 nanoviricide 59 cellular immunotherapy 59 novel histone deacetylase 59 GRN# 59 lintuzumab SGN 59 humanized monoclonal antibodies 59 SAR# [002] 59 NASH Huntington 59 Exelixis XL# 59 Neugene 59 Liposomal 59 PI3K inhibitor 59 p# inhibitor 59 investigational hepatitis B 59 HCV NS5B polymerase 59 riociguat 59 Alferon N 59 PEGylated Fab fragment 59 ENMD # 59 BiTE antibody 59 H#N# VLP vaccine 59 dimebon latrepirdine 59 Mipomersen 59 selective modulator 59 rNAPc2 59 StaphVAX R 59 SNT MC# 59 HGS ETR1 59 RIGScan CR 59 topical anti infective 59 cathepsin K inhibitor 59 CCR5 antagonist 59 intranasal formulation 59 Phase IIa clinical 59 Aviptadil 59 BZL# 59 Onalta ™ 59 IND Filing 59 TRX1 59 ProMune 59 AAV vector 59 Preclinical Data 59 Actilon 59 Azedra TM 59 sJIA 59 hyperphenylalaninemia HPA due 59 torsemide ER 59 systemically administered 59 Bevasiranib 59 antisense inhibitor 59 PRT# 59 Silodosin 59 THR beta agonist 59 Clevudine 59 Initiates Enrollment 59 pharmacogenetic test 59 Urocortin 2 59 R roscovitine 59 TLK# 59 REMOXY R 59 PXD# 59 PDX pralatrexate 59 therapeutic peptide 59 Valortim 59 phase Ib 59 TÎ ² 4 59 SinuNase TM 59 oral dnaJP1 59 Nasdaq MITI biopharmaceutical 59 Glufosfamide 59 BiTE 59 PKC# 59 OMNARIS HFA 59 HCV protease inhibitor 59 JAK Inhibitor 59 Insegia 59 relapsed leukemia 59 obatoclax 59 MT#/MEDI-# 59 elotuzumab 59 Aryplase 59 Zenvia ™ 59 LPM TM 59 Cleviprex TM clevidipine 59 therapeutic monoclonal antibodies 59 MAXY VII 59 mGluR2 positive 59 HCV polymerase inhibitors 59 Atacicept 59 biologic therapeutics 59 Initiates Clinical Trial 59 Aplidin 59 HCV polymerase inhibitor 59 PROSTASCINT R 59 HuCAL antibodies 59 nephropathic cystinosis 59 Potelligent Technology 59 Sapacitabine 59 Nasdaq SGMO announced 59 cyclophilin inhibitors 59 delta opioid receptor 59 anti infective treatments 59 Alfacell proprietary ribonuclease 59 vemurafenib 59 buccal delivery 59 ocrelizumab 59 Tezampanel 59 recombinant influenza 59 mTOR kinase 59 initiate Phase 1b 59 #beta HSD1 59 Nicotine Conjugate Vaccine 59 optimal dosing regimens 59 REMOXY ® 59 ulimorelin 59 immuno inflammatory 59 glucagon receptor 59 depsipeptide 59 JAK2 inhibitors 59 mGluR5 antagonist 59 Phase #b/#a clinical 59 treat chronic sinusitis 59 novel L DOS# 59 Late Breaker 59 Stapled Peptide 59 TransVax ™ 59 Phase #b/#a trial 59 dexpramipexole 59 fusion inhibitor 59 neurotrophic 59 Cloretazine R 59 peptibody 59 PORxin TM 59 inhibitor RG# 59 teplizumab 59 MOZOBIL 58 pafuramidine 58 Bayer HealthCare Onyx Pharmaceuticals 58 novel peptides 58 Golimumab 58 UPLYSO 58 Zoraxel 58 Serdaxin 58 oral proteasome inhibitor 58 Locked Nucleic Acid LNA 58 Phase IIB 58 inflammatory autoimmune diseases 58 NEUGENE antisense 58 pharmacodynamic PD 58 RNAi therapeutic 58 midstage clinical 58 NGX# 58 proprietary PEGylation 58 Vaccine Candidate 58 vaginally administered lidocaine 58 generation URAT1 inhibitor 58 pharmacokinetic PK study 58 rALLy clinical trial 58 TYZEKA 58 kallikrein 58 PDE# inhibitors 58 genomic biomarker 58 HCV nucleoside polymerase inhibitors 58 lexidronam injection 58 Omacetaxine 58 preclinical pharmacokinetic 58 Announces Poster Presentations 58 telaprevir VX 58 SPRYCEL ® 58 ZFNs 58 Carfilzomib 58 Combination REOLYSIN R 58 XmAb# 58 Phase Ib II 58 TRAIL Receptor 58 DepoVax TM 58 pre exposure prophylaxis 58 histone deacetylase inhibitor 58 allosteric modulator NAM 58 PEG SN# 58 Pervasis 58 YONDELIS 58 EGFR HER 58 Cand5 58 VEGF inhibitors 58 ZEVALIN ® 58 delta isoform 58 Vitrasert ® 58 HCV protease 58 teriflunomide 58 Dasatinib 58 delivery polymer matrix 58 STRIDE PD 58 generation antisense 58 Present Preclinical Data 58 Radezolid 58 Tofacitinib 58 tremelimumab 58 quinacrine 58 class mGluR5 inhibitor 58 ChronVac C R 58 HuMax CD4 58 Cogane 58 endothelin receptor 58 Systemic Sclerosis 58 Proxinium TM 58 eniluracil 58 First Patient Dosed 58 Vaxfectin 58 PI3K/Akt pathway inhibitor 58 enhance ApoA 58 OTCBB NRGX 58 Vaxfectin TM formulated 58 fibrotic disease 58 GMX# 58 potent suppressor 58 Temsirolimus 58 candidate TNFerade biologic 58 ALTROPANE R 58 HCV RNA polymerase 58 diabetic kidney 58 ELND-#/AZD-# 58 BAL# [002] 58 Ceflatonin R 58 TOCOSOL Camptothecin 58 Tarvacin Anti Cancer 58 dacetuzumab 58 phase IIb 58 antisense inhibitors 58 HEPLISAV ™ 58 Myelodysplastic Syndrome MDS 58 RhuDex R 58 antisense drugs 58 blood serum biomarkers 58 vascular disrupting agents 58 BCX# 58 TBC# 58 HepaGam B 58 Antisense 58 custirsen 58 #th Interscience Conference 58 Tarvacin 58 registrational trial 58 rhFVIIa 58 demonstrated antitumor activity 58 oral JAK1 58 XL# XL# 58 Diabetic Neuropathy 58 Acute Radiation Syndrome ARS 58 IMC #B 58 imatinib resistance 58 FTIs 58 Nalmefene 58 Diamyd R 58 Efficacy Trial 58 neurogenic orthostatic hypotension 58 OMP #R# 58 recombinant PSMA vaccine 58 GeneICE 58 Nasdaq SGMO 58 GAMMAGARD 58 IIa clinical 58 Novel Oral 58 mGluR5 negative 58 dyskinesia PD LID 58 Valortim R 58 personalized cellular immunotherapy 58 Zenvia Phase III 58 small molecule agonists 58 Phase IIA 58 Neuvenge 58 ruxolitinib 58 5 HT2A serotonin 58 drug pipeline TAFA# 58 Phase IIb III 58 recurrent glioma 58 Androxal TM 58 Selective Electrochemical Tumor Ablation 58 immunomodulator 58 tubulin inhibitor 58 peptidic compound 58 JAK3 58 commercialize deforolimus 58 orally bioavailable 58 albiglutide 58 Plicera 58 epothilone 58 maturation inhibitor 58 2 methoxyestradiol 58 Enzastaurin 58 PSMA ADC 58 GSK # 58 RELOVAIR ™ 58 Aeolus Pharmaceuticals Announces 58 DAS# [001] 58 orally dosed 58 Alocrest 58 pralatrexate injection folate analogue 58 CORT # 58 Synavive 58 Ramoplanin 58 preclinical compounds 58 HGS ETR1 mapatumumab 58 SomatoKine 58 sodium glucose cotransporter 58 BRAF inhibitors 58 Maxy G# 58 signal transduction inhibitor 58 Sangamo ZFP technology 58 platform HDL Mimetic 58 REG2 58 negative allosteric modulator 58 DOS# 58 PCK# 58 ddRNAi 58 Dupuytren Contracture 58 ADVEXIN p# therapy 58 Annamycin 58 modified glutathione analog 58 Patient Enrollment 58 evaluating tivozanib 58 Optiquel ™ 58 presymptomatic 58 peptide antigens 58 LE DT 58 immune modulatory 58 Tβ4 58 evaluating mipomersen 58 HIV integrase inhibitor 58 Abstract Accepted 58 ORENCIA R 58 oral salmon calcitonin 58 Panzem R NCD 58 Gleevec imatinib mesylate 58 Lisofylline 58 Nektar proprietary 58 TELINTRA 58 ZFNs clinical trials 58 mGluR5 antagonists 58 Daclizumab 58 nucleoside analog 58 hyaluronidase enzyme 58 VEGFR2 inhibitor 58 PDGF receptor 58 GVAX R 58 Evoltra ® 58 Interferon beta 58 Infected Patients 58 Inc. OTCBB IRBS 58 Janus Kinase 58 Scancell 58 TKM PLK1 58 TLR9 agonist 58 Integrase Inhibitor 58 pan HDAC inhibitor 58 Gleevec resistant 58 NurOwn 58 zileuton CR 58 novel antibody therapeutics 58 systemic juvenile idiopathic 58 vivo preclinical 58 antiangiogenesis therapies 58 TNFerade TM 58 trodusquemine 58 lumiliximab 58 p# biomarker 58 phase IIb trial 58 vivo toxicology 58 oral RSD# 58 hypoxia activated prodrug 58 ProSavin 58 PEGylated 58 Testosterone MDTS ® 58 selective kinase inhibitor 58 Vascugel 58 Vascular Disrupting Agent 58 aurora kinase 58 HGS ETR2 58 ANG# 58 TransVax TM 58 MAXY alpha 58 taxane derivative 58 Alemtuzumab 58 assessing T DM1 58 Corgentin 58 cediranib 58 ganetespib 58 Lipid Sciences 58 vivo efficacy 58 metastatic colorectal 58 Pancreas Cancer Vaccine 58 ADVEXIN clinical 58 Maribavir 58 investigational protease inhibitor 58 ALN HTT 58 XL# anticancer compounds 58 AQ4N 58 Cobalamin 58 catalytic antioxidant compounds 58 Ultrafast Insulin 58 Presents Positive 58 Sudhir Agrawal D.Phil 58 VivaGel TM 58 lomitapide 58 Vacc 4x 58 AA Amyloidosis 58 Curaxins 58 AZX# 58 MAP# 58 LHRH antagonists 58 Saforis 58 BENLYSTA ® 58 MORAb 58 PEGylated interferon 58 Davunetide 58 SAR# [004] 58 vaccine GRNVAC1 58 Rasagiline 58 Romiplostim 58 Adenosine A2A 58 recombinant subunit vaccine 58 Bortezomib 58 Onalta 58 hypophosphatasia 58 thetreatment 57 panitumumab Vectibix 57 dirucotide MBP# 57 Ofatumumab 57 novel RNAi therapeutics 57 kinase inhibition 57 MEK inhibitors 57 Sym# 57 elacytarabine 57 Quinamed 57 Wnt signaling pathway 57 vivo pharmacology 57 BARACLUDE R 57 candidate XP# 57 TPI ASM8 57 MT# MEDI 57 selective immunoproteasome inhibitor 57 bardoxolone methyl 57 chemotherapy induced neutropenia 57 systemic RNAi